ID E4OR1_ADE09 Reviewed; 125 AA. AC P89079; DT 12-APR-2005, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1997, sequence version 1. DT 14-DEC-2022, entry version 87. DE RecName: Full=E4-ORF1; DE EC=3.6.1.23; DE AltName: Full=Early E4 14.0 kDa protein; DE AltName: Full=ORF1; DE AltName: Full=Probable dUTPase E4 ORF1; GN Name=E4; OS Human adenovirus D serotype 9 (HAdV-9) (Human adenovirus 9). OC Viruses; Varidnaviria; Bamfordvirae; Preplasmiviricota; Tectiliviricetes; OC Rowavirales; Adenoviridae; Mastadenovirus; Human mastadenovirus D. OX NCBI_TaxID=10527; OH NCBI_TaxID=9606; Homo sapiens (Human). RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=8738606; DOI=10.1007/bf01806078; RA Javier R.T., Shenk T.; RT "Mammary tumors induced by human adenovirus type 9: a role for the viral RT early region 4 gene."; RL Breast Cancer Res. Treat. 39:57-67(1996). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RC STRAIN=Isolate ATCC VR-1086 / Hicks / V-209-003-014; RA Buettner W.H., Veres-Molnar S.K.; RT "Adenovirus type 9, complete sequence."; RL Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP FUNCTION AS ONCOGENE. RX PubMed=8189528; DOI=10.1128/jvi.68.6.3917-3924.1994; RA Javier R.T.; RT "Adenovirus type 9 E4 open reading frame 1 encodes a transforming protein RT required for the production of mammary tumors in rats."; RL J. Virol. 68:3917-3924(1994). RN [4] RP SUBCELLULAR LOCATION, AND MUTAGENESIS OF 34-PHE--VAL-41; LEU-89; PHE-91; RP ALA-122 AND 123-THR--VAL-125. RX PubMed=9151828; DOI=10.1128/jvi.71.6.4385-4394.1997; RA Weiss R.S., Gold M.O., Vogel H., Javier R.T.; RT "Mutant adenovirus type 9 E4 ORF1 genes define three protein regions RT required for transformation of CREF cells."; RL J. Virol. 71:4385-4394(1997). RN [5] RP INTERACTION WITH HUMAN MPDZ, AND MUTAGENESIS OF ALA-122; 123-THR--VAL-125 RP AND LEU-124. RX PubMed=11000240; DOI=10.1128/jvi.74.20.9680-9693.2000; RA Lee S.S., Glaunsinger B., Mantovani F., Banks L., Javier R.T.; RT "Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus RT E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins."; RL J. Virol. 74:9680-9693(2000). CC -!- FUNCTION: Plays a key role in virus oncogenecity in animals. Binds and CC sequesters human MUPP1/MPDZ protein in the cytoplasm, preventing it CC from playing a role in cellular proliferation regulation. Induces cell CC transformation, probably by inactivating MPDZ protein. CC {ECO:0000269|PubMed:8189528}. CC -!- CATALYTIC ACTIVITY: CC Reaction=dUTP + H2O = diphosphate + dUMP + H(+); Xref=Rhea:RHEA:10248, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:33019, CC ChEBI:CHEBI:61555, ChEBI:CHEBI:246422; EC=3.6.1.23; CC -!- SUBUNIT: Binds to human MPDZ. CC -!- INTERACTION: CC P89079; Q62696: Dlg1; Xeno; NbExp=4; IntAct=EBI-7401124, EBI-389325; CC -!- SUBCELLULAR LOCATION: Host cytoplasm {ECO:0000269|PubMed:9151828}. CC -!- SIMILARITY: Belongs to the dUTPase family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; S82508; AAB37504.1; -; Genomic_DNA. DR EMBL; AJ854486; CAI05991.1; -; Genomic_DNA. DR SMR; P89079; -. DR DIP; DIP-44835N; -. DR ELM; P89079; -. DR IntAct; P89079; 3. DR MINT; P89079; -. DR Proteomes; UP000118285; Genome. DR GO; GO:0030430; C:host cell cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0004170; F:dUTP diphosphatase activity; IEA:UniProtKB-EC. DR GO; GO:0009117; P:nucleotide metabolic process; IEA:UniProtKB-KW. DR Gene3D; 2.70.40.10; -; 1. DR InterPro; IPR029054; dUTPase-like. DR InterPro; IPR036157; dUTPase-like_sf. DR Pfam; PF00692; dUTPase; 1. DR SUPFAM; SSF51283; dUTPase-like; 1. PE 1: Evidence at protein level; KW Early protein; Host cytoplasm; Host-virus interaction; Hydrolase; KW Nucleotide metabolism; Oncogene. FT CHAIN 1..125 FT /note="E4-ORF1" FT /id="PRO_0000221784" FT MOTIF 122..125 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT MUTAGEN 34..41 FT /note="FHIPPHGV->IHIPPQGA: Complete loss of FT transformation." FT /evidence="ECO:0000269|PubMed:9151828" FT MUTAGEN 89 FT /note="L->Q: Complete loss of transformation." FT /evidence="ECO:0000269|PubMed:9151828" FT MUTAGEN 91 FT /note="F->S: Complete loss of transformation." FT /evidence="ECO:0000269|PubMed:9151828" FT MUTAGEN 122 FT /note="A->D: Partial loss of transformation. Complete loss FT of binding to MPDZ. Localizes aberrantly in the nucleus." FT /evidence="ECO:0000269|PubMed:11000240, FT ECO:0000269|PubMed:9151828" FT MUTAGEN 123..125 FT /note="TLV->P: Complete loss of transformation. Complete FT loss of binding to MPDZ. Localizes aberrantly in the FT nucleus." FT /evidence="ECO:0000269|PubMed:11000240, FT ECO:0000269|PubMed:9151828" FT MUTAGEN 124 FT /note="L->P: Partial loss of transformation. Partial loss FT of binding to MPDZ. Localizes aberrantly in the nucleus." FT /evidence="ECO:0000269|PubMed:11000240" SQ SEQUENCE 125 AA; 14041 MW; 75792A75E484BC09 CRC64; MAESLYAFID SPGGIAPVQE GTSNRYTFFC PESFHIPPHG VVLLHLKVSV LVPTGYQGRF MALNDYHARD ILTQSDVIFA GRRQELTVLL FNHTDRFLYV RKGHPVGTLL LERVIFPSVK IATLV //